Armata Pharmaceuticals, Inc. (ARMP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5005 MCCONNELL AVE LOS ANGELES, CA 90066 |
| State of Incorp. | WA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 13,523,000 | 14,852,000 | 10,288,000 | 9,649,000 | 6,033,000 | 8,157,000 | |||
| Cash and cash equivalent | 13,523,000 | 14,852,000 | 10,288,000 | 9,649,000 | 6,033,000 | 8,157,000 | |||
| Receivables | 3,363,000 | ||||||||
| Other current assets | 3,363,000 | ||||||||
| Other undisclosed current assets | (1,098,000) | 12,195,000 | 4,707,000 | 1,197,000 | 622,000 | 251,000 | |||
| Total current assets: | 19,151,000 | 27,047,000 | 14,995,000 | 10,846,000 | 6,655,000 | 8,408,000 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 44,717,000 | 43,035,000 | 35,852,000 | 10,790,000 | 2,028,000 | ✕ | |||
| Property, plant and equipment | 12,559,000 | 3,617,000 | 2,220,000 | 2,047,000 | 2,187,000 | 503,000 | |||
| Intangible assets, net (including goodwill) | 13,746,000 | 13,746,000 | 13,746,000 | 13,746,000 | 13,746,000 | 2,731,000 | |||
| Goodwill | 3,490,000 | 3,490,000 | 3,490,000 | 3,490,000 | 3,490,000 | ||||
| Intangible assets, net (excluding goodwill) | 10,256,000 | 10,256,000 | 10,256,000 | 10,256,000 | 10,256,000 | 2,731,000 | |||
| Restricted cash and investments | 5,720,000 | 5,960,000 | 1,200,000 | 1,200,000 | 700,000 | ||||
| Other noncurrent assets | 2,470,000 | 2,429,000 | 1,755,000 | 887,000 | 135,000 | ||||
| Other undisclosed noncurrent assets | 245,000 | ||||||||
| Total noncurrent assets: | 79,212,000 | 68,787,000 | 54,773,000 | 28,670,000 | 18,796,000 | 3,479,000 | |||
| TOTAL ASSETS: | 98,363,000 | 95,834,000 | 69,768,000 | 39,516,000 | 25,451,000 | 11,887,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 5,689,000 | 6,034,000 | 2,270,000 | 1,929,000 | 1,278,000 | 2,572,000 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | 38,000 | |||||
| Employee-related liabilities | ✕ | ✕ | ✕ | 1,352,000 | |||||
| Accounts payable | 1,585,000 | 1,678,000 | 1,138,000 | 956,000 | 547,000 | 729,000 | |||
| Other undisclosed accounts payable and accrued liabilities | 4,104,000 | 4,356,000 | 1,132,000 | 973,000 | 731,000 | 453,000 | |||
| Debt | 1,308,000 | ||||||||
| Deferred compensation liability | 768,000 | 1,828,000 | 1,035,000 | 563,000 | 1,323,000 | ||||
| Business combination, contingent consideration, liability | 1,940,000 | 970,000 | |||||||
| Other liabilities | 523,000 | ||||||||
| Other undisclosed current liabilities | 9,481,000 | 17,011,000 | 1,509,000 | 2,273,000 | |||||
| Total current liabilities: | 16,461,000 | 24,873,000 | 4,814,000 | 6,705,000 | 4,879,000 | 2,572,000 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 82,307,000 | 36,480,000 | 10,877,000 | 1,555,000 | |||||
| Long-term debt, excluding current maturities | 82,307,000 | ||||||||
| Liabilities, other than long-term debt | 31,660,000 | 34,881,000 | 3,077,000 | 3,077,000 | 4,424,000 | 841,000 | |||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 819,000 | ||
| Deferred income tax liabilities | 3,077,000 | 3,077,000 | 3,077,000 | 3,077,000 | 3,077,000 | ✕ | |||
| Operating lease, liability | 28,583,000 | 31,804,000 | 36,480,000 | 10,877,000 | 1,555,000 | ✕ | |||
| Business combination, contingent consideration, liability | 1,347,000 | ||||||||
| Derivative instruments and hedges, liabilities | 22,000 | ||||||||
| Total noncurrent liabilities: | 113,967,000 | 34,881,000 | 39,557,000 | 13,954,000 | 5,979,000 | 841,000 | |||
| Total liabilities: | 130,428,000 | 59,754,000 | 44,371,000 | 20,659,000 | 10,858,000 | 3,413,000 | |||
| Equity | |||||||||
| Equity, attributable to parent | (32,065,000) | 36,080,000 | 25,397,000 | 18,857,000 | 14,593,000 | 8,474,000 | |||
| Common stock | 361,000 | 361,000 | 271,000 | 187,000 | 99,000 | 323,000 | |||
| Additional paid in capital | 276,393,000 | 275,493,000 | 227,983,000 | 198,372,000 | 172,015,000 | 414,467,000 | |||
| Accumulated deficit | (308,819,000) | (239,774,000) | (202,857,000) | (179,702,000) | (157,521,000) | (406,316,000) | |||
| Total equity: | (32,065,000) | 36,080,000 | 25,397,000 | 18,857,000 | 14,593,000 | 8,474,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 98,363,000 | 95,834,000 | 69,768,000 | 39,516,000 | 25,451,000 | 11,887,000 | |||
Income Statement (P&L) (USD)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (45,419,000) | (42,454,000) | (28,296,000) | (22,410,000) | (19,752,000) | (12,524,000) | ||
| Other undisclosed operating income | 4,529,000 | 5,508,000 | 4,474,000 | 823,000 | ||||
| Operating loss: | (40,890,000) | (36,946,000) | (23,822,000) | (21,587,000) | (19,752,000) | (12,524,000) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (28,155,000) | 29,000 | 667,000 | (594,000) | 273,000 | 86,000 | ||
| Interest and debt expense | (3,863,000) | (64,000) | (628,000) | (931,000) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 628,000 | 931,000 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (72,908,000) | (36,917,000) | (23,219,000) | (22,181,000) | (19,479,000) | (12,438,000) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 72,838,955 | 64,000 | ||||||
| Loss from continuing operations before income taxes: | (69,045) | (36,917,000) | (23,155,000) | (22,181,000) | (19,479,000) | (12,438,000) | ||
| Income tax benefit | 328,000 | |||||||
| Loss from continuing operations: | (69,045) | (36,917,000) | (23,155,000) | (22,181,000) | (19,479,000) | (12,110,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (23,155,000) | (22,181,000) | (19,479,000) | (12,110,000) | |
| Other undisclosed net loss | (68,975,955) | |||||||
| Net loss available to common stockholders, basic: | (69,045,000) | (36,917,000) | (23,155,000) | (22,181,000) | (19,479,000) | (12,110,000) | ||
| Dilutive securities, effect on basic earnings per share | ||||||||
| Other undisclosed net loss available to common stockholders, diluted | (938,000) | (55,000) | ||||||
| Net loss available to common stockholders, diluted: | (69,045,000) | (36,917,000) | (23,155,000) | (22,181,000) | (20,417,000) | (12,165,000) | ||
Comprehensive Income (USD)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (69,045,000) | (36,917,000) | (23,155,000) | (22,181,000) | (19,479,000) | (12,110,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (69,045,000) | (36,917,000) | (23,155,000) | (22,181,000) | (19,479,000) | (12,110,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.